RNA-seq profiling of paralysed CD8 negative dendritic cells after systemic inflammatory syndrome
Ontology highlight
ABSTRACT:
ORGANISM(S): Mus musculus
PROVIDER: GSE207845 | GEO | 2024/01/04
REPOSITORIES: GEO
Similar Datasets
Project description:CD8 dendritic cells were harvested from the spleens of treated and untreated mice. Treated mice were innoculated intravenously with 40nmol of CpG1680 to induce systematic inflammation five days before harvesting cells. Cells from the treated mice show high CD103 expression. Cells from the untreated mice were FACS sorted based on CD103 expression into CD103 positive (low) and CD103 negative populations. RNA was extracted and profiled by RNA-seq. Two or three independent experiments were performed for each population, with 8 mice per group.
2024-01-04 | GSE68697 | GEO
Project description:To understand the role of LSD1 in B cell differentiation, mice with B cell conditional deletion of LSD1 were intravenously inoculated with LPS. After 3 days, B220+GL7-CD138- naïve B cells and CD138+ plasmablasts were FACS-sorted from the spleens and RNA-seq was performed to identify LSD1-target regulated genes.
2018-09-06 | GSE114775 | GEO
Project description:To understand the role of LSD1 in B cell differentiation, mice with B cell conditional deletion of LSD1 were intravenously inoculated with LPS. After 3 days, B220+GL7-CD138- naïve B cells and CD138+ plasmablasts were FACS-sorted from the spleens and RNA-seq was performed to identify LSD1-target regulated chromatin.
2018-09-06 | GSE114774 | GEO
Project description:Severe malaria encompasses a range of syndromes manifesting systemically or in diverse organs. These are believed to represent the end-stage processes of local parasite sequestration and inflammatory cascades. Classical anti-malarial drugs target parasites only. In treatment of severe disease, adjunctive therapies capable of controlling the inflammatory processes could be beneficial. Innate defense regulator (IDR) peptides display multiple immune modulatory activities. In this study, we assessed peptide IDR-1018, which shows promise as an anti-inflammatory drug, as a lead candidate for adjunctive host-directed therapy of established disease in the P. berghei ANKA model of experimental cerebral malaria (ECM). Intravenously administered IDR-1018 partially protected mice from ECM both prophylactically and in adjunctive treatment with classical anti-malarial drugs. We used transcriptional data from spleens and brains taken early in infection (day 3) of prophylactically treated mice to investigate the protective mechanisms. The microarrays compared spleens and brains from nine IDR-1018 i.v. treated, infected mice (IDR-1018-treated infected) with three saline i.v. treated infected mice (saline-treated infected) and three uninfected untreated control mice (controls). RNA samples were hybridized in randomized order to five Illumina WG-6 v2 BeadChips . No technical replicates were performed.
2012-04-08 | E-GEOD-32007 | biostudies-arrayexpress
Project description:This submission contains raw data obtained from RNA sequencing of mouse spleen cells. Spleen cells were derived from adult female HLA-DQ8, huCD4 transgenic Ab0 NOD mice, treated intravenously either with tolerogenic, immune-modifying nanoparticles containing gliadin (TIMP-GLIA), particles containing irrelevant control ovalbumin (TIMP-OVA), or not receiving treatment. Mice were then immunized with gliadin (except for negative controls), and spleens were collected after 28-30 days. Spleen cells were stimulated with gliadin (or controls) in culture for 72h, and RNA was obtained from cells for transcriptomic studies.
2019-11-21 | GSE140736 | GEO
Project description:Eumyc lymphoma was inoculated i.v. into C57BL/6J mice. Spleens were harvested from healthy or Emyc lymphoma-bearing mice at day 14 post-inoculation, and splenic NK cells were purfied using flow cytometry.
2020-09-01 | GSE121448 | GEO
Project description:A split-split-plot design with 144 experimental units (3 replications x 4 genotypes x 6 time points x 2 treatment types) was used to profile barley plants containing variants of Mla1 and Mla6 powdery mildew resistance genes in response to inoculation with the Blumeria graminis f. sp. hordei (Bgh) isolates 5874 (AvrMla1, AvrMla6). Barley leaves were harvested from inoculated and non-inoculated plants at 6 time points (0,8,16,20,24 and 32 hrs) after Bgh inoculation. ****[PLEXdb(http://www.plexdb.org) has submitted this series at GEO on behalf of the original contributor, Rico Caldo. The equivalent experiment is BB10 at PLEXdb.] genotype: Mla1 - time: 0 - Treated or untreated: Inoculated (3-replications); genotype: Mla1 - time: 0 - Treated or untreated: Non-inoculated(3-replications); genotype: Mla1 - time: 8 - Treated or untreated: Inoculated (3-replications); genotype: Mla1 - time: 8 - Treated or untreated: Non-inoculated(3-replications); genotype: Mla1 - time: 16 - Treated or untreated: Inoculated (3-replications); genotype: Mla1 - time: 16 - Treated or untreated: Non-inoculated(3-replications); genotype: Mla1 - time: 20 - Treated or untreated: Inoculated (3-replications); genotype: Mla1 - time: 20 - Treated or untreated: Non-inoculated(3-replications); genotype: Mla1 - time: 24 - Treated or untreated: Inoculated (3-replications); genotype: Mla1 - time: 24 - Treated or untreated: Non-inoculated(3-replications); genotype: Mla1 - time: 32 - Treated or untreated: Inoculated (3-replications); genotype: Mla1 - time: 32 - Treated or untreated: Non-inoculated(3-replications); genotype: m508 - time: 0 - Treated or untreated: Inoculated (3-replications); genotype: m508 - time: 0 - Treated or untreated: Non-inoculated(3-replications); genotype: m508 - time: 8 - Treated or untreated: Inoculated (3-replications); genotype: m508 - time: 8 - Treated or untreated: Non-inoculated(3-replications); genotype: m508 - time: 16 - Treated or untreated: Inoculated (3-replications); genotype: m508 - time: 16 - Treated or untreated: Non-inoculated(3-replications); genotype: m508 - time: 20 - Treated or untreated: Inoculated (3-replications); genotype: m508 - time: 20 - Treated or untreated: Non-inoculated(3-replications); genotype: m508 - time: 24 - Treated or untreated: Inoculated (3-replications); genotype: m508 - time: 24 - Treated or untreated: Non-inoculated(3-replications); genotype: m508 - time: 32 - Treated or untreated: Inoculated (3-replications); genotype: m508 - time: 32 - Treated or untreated: Non-inoculated(3-replications); genotype: Mla6 - time: 0 - Treated or untreated: Inoculated (3-replications); genotype: Mla6 - time: 0 - Treated or untreated: Non-inoculated(3-replications); genotype: Mla6 - time: 8 - Treated or untreated: Inoculated (3-replications); genotype: Mla6 - time: 8 - Treated or untreated: Non-inoculated(3-replications); genotype: Mla6 - time: 16 - Treated or untreated: Inoculated (3-replications); genotype: Mla6 - time: 16 - Treated or untreated: Non-inoculated(3-replications); genotype: Mla6 - time: 20 - Treated or untreated: Inoculated (3-replications); genotype: Mla6 - time: 20 - Treated or untreated: Non-inoculated(3-replications); genotype: Mla6 - time: 24 - Treated or untreated: Inoculated (3-replications); genotype: Mla6 - time: 24 - Treated or untreated: Non-inoculated(3-replications); genotype: Mla6 - time: 32 - Treated or untreated: Inoculated (3-replications); genotype: Mla6 - time: 32 - Treated or untreated: Non-inoculated(3-replications); genotype: 9472 - time: 0 - Treated or untreated: Inoculated (3-replications); genotype: 9472 - time: 0 - Treated or untreated: Non-inoculated(3-replications); genotype: 9472 - time: 8 - Treated or untreated: Inoculated (3-replications); genotype: 9472 - time: 8 - Treated or untreated: Non-inoculated(3-replications); genotype: 9472 - time: 16 - Treated or untreated: Inoculated (3-replications); genotype: 9472 - time: 16 - Treated or untreated: Non-inoculated(3-replications); genotype: 9472 - time: 20 - Treated or untreated: Inoculated (3-replications); genotype: 9472 - time: 20 - Treated or untreated: Non-inoculated(3-replications); genotype: 9472 - time: 24 - Treated or untreated: Inoculated (3-replications); genotype: 9472 - time: 24 - Treated or untreated: Non-inoculated(3-replications); genotype: 9472 - time: 32 - Treated or untreated: Inoculated (3-replications); genotype: 9472 - time: 32 - Treated or untreated: Non-inoculated(3-replications)
2011-11-22 | E-GEOD-33392 | biostudies-arrayexpress
Project description:Mice were inoculated with Listeria by i.p. injection on days 0 and 11. On day 18, FSC(high)CD4(+)CD8(-)B220(-)MHCII(-) T cells were FACS-sorted from spleens for single cell RNAseq.
2018-07-17 | GSE117166 | GEO
Project description:In order to identify genes expressed by cells that leave the spleen, the spleens were harvested from untreated reconstituted humanized mice (N=4) and a single cell suspension was prepared . The cultures were treated with either teplizumab (anti human CD3 hOKT3g1(Ala-Ala)) or hIg for 18 hrs in vitro. Splenocytes were also harvested 18 hrs after reconstituted mice (N=4) were treated with teplizumab in vivo. The humanized mice used where NOD/SCID IL2gc-/- (NSG) reconstituted with human CD34+ at birth.
2012-02-27 | GSE34163 | GEO
Project description:Naive spleens as well as naive and LPS-treated dendritic cells from wildtype and GPR34-/- mice were sequenced to integrate expression profiles with protein interaction networks and find functional modules that are affected by GPR34
2016-03-02 | GSE68155 | GEO